Immutep Limited: Immutep Quarterly Activities Report Q2 FY25
Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...
Immutep Quarterly Activities Report Q2 FY25
Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...
eLife1 天
Molecular Feature-Based Classification of Retroperitoneal Liposarcoma: A Prospective Cohort ...
Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Disease, Beijing ...
News Medical3 天
New treatment identified for peripheral nerve sheath tumors
A multicenter collaboration led by the Bellvitge Biomedical Research Institute (IDIBELL) - Institut Català d'Oncologia (ICO) ...
Triple combination of inhibitors emerges as potential new treatment for aggressive cancer
A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...